Polymorphisms and high on-aspirin platelet reactivity after off-pump coronary artery bypass grafting

Scand Cardiovasc J. 2013 Aug;47(4):194-9. doi: 10.3109/14017431.2013.800640. Epub 2013 May 31.

Abstract

Objectives: High on-aspirin residual platelet reactivity (RPR) after coronary artery bypass grafting (CABG) is a transient phenomenon with important implications for graft patency. This study was designed to determine the role of polymorphisms [TBXA2R (T924C), GPIIIa (Pl(A1/A2)), P2Y1 (A1622G), and GP1Bα (C1018T)] on RPR in Chinese patients undergoing off-pump CABG (OPCAB).

Methods: Of 420 patients recruited to this study, 210 patients underwent primary OPCAB and 210 controls with ischemic heart disease received optimal medical therapy. Arachidonic acid-induced platelet aggregation and urinary 11-dehydro thromboxane B2 were measured at baseline and following aspirin administration on days 1, 4, 10, and on 6th month. Four polymorphisms were identified [TBXA2R (T924C), P2Y1 (A1622G), Pl(A1/A2) and GP1Bα (C1018T)].

Results: On the first post-operative day, 62 patients (29.5%) were with high RPR and 148 (70.5%) were with low RPR. Of the former, 33 (15.7%), 10 (4.6%), and 0 (0%) patients remained with high RPR on days 4, 10, and on 6 month, respectively. No individuals with high RPR was found in controls. Logistic regression identified TBXA2R-924TT (OR = 4.5; 95% CI, 1.8-11.1) and body mass index > 27 kg/m(2) (OR = 2.73; 95% CI, 1.1-7.0) as independent risk factors for high on-aspirin RPR.

Conclusions: High on-aspirin RPR after OPCAB is associated with genetic polymorphism TBXA2R-924TT and obesity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Analysis of Variance
  • Asian People / genetics
  • Aspirin / therapeutic use*
  • Case-Control Studies
  • Chi-Square Distribution
  • China
  • Coronary Artery Bypass*
  • Drug Resistance / genetics*
  • Female
  • Gene Frequency
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / genetics
  • Pharmacogenetics
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Function Tests
  • Polymorphism, Genetic*
  • Receptors, Thromboxane A2, Prostaglandin H2 / genetics*
  • Risk Factors
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Receptors, Thromboxane A2, Prostaglandin H2
  • Aspirin